Portal de investigación
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Alonso, Rafael
- Clavero, Maria Esther
- Askari, Elham
- Garcia, Alfonso
- Anton, Cristina
- Fernandez, Margarita
- Escalante, Fernando
- Garcia, Ana
- Rios-Tamayo, Rafael
- Conesa, Venancio
- Bermudez, Maria Arancha
- Merchan, Beatriz
- Velasco, Alberto E.
- Blanchard, Maria Jesus
- Sampol, Antonia
- Gainza, Eukene
- Hernandez, Prisma Montserrat
- Alegre, Adrian
Grupos
Abstract
Belantamab-mafodotin (belamaf) is a novel antibody-drug conjugate targeting B-cell maturation antigen that showed anti-myeloma activity in patients with relapsed and refractory multiple myeloma (RRMM). We performed an observational, retrospective, and multicenter study aimed to assess the efficacy and safety of single-agent belamaf in 156 Spanish patients with RRMM. The median number of prior therapy lines was 5 (range, 1-10), and 88% of patients were triple-class refractory. Median follow-up was 10.9 months (range, 1-28.6). The overall response rate was 41.8% (=CR 13.5%, VGPR 9%, PR 17.3%, MR 2%). The median progression-free survival was 3.61 months (95% CI, 2.1-5.1) and 14.47 months (95% CI, 7.91-21.04) in patients achieving at least MR (p < 0.001). Median overall survival in the entire cohort and in patients with MR or better was 11.05 months (95% CI, 8.7-13.3) and 23.35 (NA-NA) months, respectively (p < 0.001). Corneal events (87.9%; grade = 3, 33.7%) were the most commonly adverse events, while thrombocytopenia and infections occurred in 15.4% and 15% of patients, respectively. Two (1.3%) patients discontinued treatment permanently due to ocular toxicity. Belamaf showed a noticeably anti-myeloma activity in this real-life series of patients, particularly among those achieving MR or better. The safety profile was manageable and consistent with prior studies.
Datos de la publicación
- ISSN/ISSNe:
- 2072-6694, 2072-6694
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 37296925
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 1,349 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Cancers MDPI
Citas Recibidas en Web of Science: 18
Citas Recibidas en Scopus: 15
Documentos
- No hay documentos
Filiaciones
Keywords
- belantamab mafodotin; multiple myeloma; refractory; relapse; treatment
Campos de Estudio
Cita
DE LA RUBIA J,Alonso R,Clavero ME,Askari E,Garcia A,Anton C,Fernandez M,Escalante F,Garcia A,Rios R,Conesa V,Bermudez MA,Merchan B,Velasco AE,Blanchard MJ,Sampol A,Gainza E,Hernandez PM,Alegre A. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. Cancers. 2023. 15. (11):2964. IF:4,500. (1).